Vagus Nerve Stimulation Shows Lasting Benefits for Severe Treatment-Resistant Depression in Two-Year Study
Key Insights
Washington University researchers found that vagus nerve stimulation (search) provided sustained improvements in depression symptoms, quality of life, and daily functioning for at least two years in patients who had failed an average of 13 previous treatments.
Among patients who showed meaningful response at one year, more than 80% maintained or improved their benefits at the two-year mark, with 92% of substantial responders still experiencing benefits.
Nearly one-third of patients who did not improve in the first year reported benefits by the end of the second year, suggesting the therapy may require extended time to work for some individuals.
Scientists at Washington University School of Medicine in St. Louis have demonstrated that vagus nerve stimulation (search) provides sustained, long-term benefits for patients with the most severe forms of treatment-resistant depression (search). The findings from the ongoing RECOVER trial, published January 13 in the International Journal of Neuropsychopharmacology, show that improvements in depressive symptoms, quality of life, and daily functioning persist for at least two years in the vast majority of patients who initially responded to the therapy.
The study represents a significant milestone for patients who have exhausted conventional treatment options. Participants had lived with depression for an average of 29 years and had already tried approximately 13 treatments without success, including intensive interventions such as electroconvulsive therapy and transcranial magnetic stimulation.
"We believe the sample in this trial represents the sickest treatment-resistant depressed patient sample ever studied in a clinical trial," said lead author Charles Conway, MD, a professor of psychiatry and director of the WashU Medicine Treatment Resistant Mood Disorders Center. "There is a dire need to find effective treatments for these patients, who often have no other options. With this kind of chronic, disabling illness, even a partial response to treatment is life-altering, and with vagus nerve stimulation (search) we're seeing that benefit is lasting."
Device Design and Mechanism
The RECOVER study evaluated whether adding vagus nerve stimulation (search) (VNS) to ongoing care could improve outcomes for people with treatment-resistant depression (search). The therapy involves surgically placing a device under the skin in the chest that sends carefully controlled electrical signals to the left vagus nerve (search), a key communication pathway between the brain and many internal organs.
The VNS Therapy System (search), manufactured by LivaNova USA, Inc. (search), which sponsored and funded the RECOVER trial, aims to influence mood-regulating brain circuits through chronic neuromodulation. The study is collecting long-term data to help the U.S. Centers for Medicare and Medicaid Services (CMS) decide whether to expand coverage for the therapy, potentially making treatment accessible to far more patients by addressing cost barriers.
Trial Design and Patient Population
Nearly 500 patients were enrolled across 84 locations in the United States. About three-quarters of participants were so severely affected by depression that they were unable to work. All patients received the implanted device, but only half had the device activated during the first year to allow for comparison between active and inactive treatment groups.
Researchers tracked changes in depression severity, quality of life, and everyday functioning. A response was considered meaningful if symptoms improved by at least 30% compared with the start of the study, while a reduction of 50% or more was classified as a "substantial" response.
Conway emphasized that even modest improvements can dramatically change a person's life, as severe depression can leave people "paralyzed by life," unable to manage basic daily activities and at higher risk of hospitalization or early death.
Sustained Benefits Over Two Years
In the newest analysis, researchers focused on the 214 patients whose devices were active from the start of the trial to determine whether improvements seen at 12 months would continue through 24 months. They also examined whether patients who did not improve in the first year might respond later with continued treatment.
Out of the 214 patients who received active treatment from the beginning, approximately 69% (147 people) showed a meaningful response at one year in at least one outcome measure. Among those who benefited at 12 months, more than 80% maintained or improved their results by the two-year mark across measures of depression, quality of life, and daily functioning.
For patients with a substantial response at one year—defined as at least a 50% reduction in symptoms—92% were still benefiting at two years. The maintenance rates were consistently high, reaching 83.1% at 18 months and 81.3% at 24 months across seven measures for those with meaningful benefit.
Delayed Response Patterns
Nearly one-third of participants who had not improved after the first year reported benefits by the end of the second year, suggesting that the therapy may take longer to work for some individuals. Among participants without meaningful benefit at 12 months, 30.6% achieved it by 18 months and 37.8% by 24 months.
Relapse rates remained low among those who responded, particularly among the strongest responders. These outcomes were not explained by changes in medications or other interventional psychiatric treatments.
Remission Rates
The researchers found that more than 20% of treated patients (39 people) were in remission after 24 months, meaning their symptoms had eased enough for them to function normally in daily life—a result Conway described as especially notable.
"We were shocked that one in five patients was effectively without depressive symptoms at the end of two years," he said. "Seeing results like that for this complicated illness makes me optimistic about the future of this treatment. These results are highly atypical, as most studies of markedly treatment-resistant depression (search) have very poor sustainability of benefit, certainly not at two years. We're seeing people getting better and staying better."
Clinical Implications
The findings suggest that vagus nerve stimulation (search) offers more than short-term symptom relief in markedly treatment-resistant depression (search). The delayed response seen in a substantial minority reinforces the need for patience and continued therapy beyond the first year.
For clinicians managing severe, refractory depression, these results support considering vagus nerve stimulation (search) earlier in long-term treatment planning and counseling patients about realistic timelines for benefit emergence and durability. The therapy appears to provide sustained neuromodulation that continues to influence mood-regulating brain circuits over extended periods.
The study's focus on real-world outpatient settings adds practical relevance to the findings, demonstrating that the benefits observed in controlled clinical conditions translate to routine clinical practice. As the research continues, the data may influence coverage decisions that could expand access to this treatment option for patients with limited alternatives.